IBDEI1NQ ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,27729,0)
 ;;=D77.^^132^1320^55
 ;;^UTILITY(U,$J,358.3,27729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27729,1,3,0)
 ;;=3^Disorder of Blood/Blood-Forming Organs in Diseases Classified Elsewhere,Other
 ;;^UTILITY(U,$J,358.3,27729,1,4,0)
 ;;=4^D77.
 ;;^UTILITY(U,$J,358.3,27729,2)
 ;;=^5002396
 ;;^UTILITY(U,$J,358.3,27730,0)
 ;;=D58.2^^132^1320^81
 ;;^UTILITY(U,$J,358.3,27730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27730,1,3,0)
 ;;=3^Hemoglobinopathies,Other
 ;;^UTILITY(U,$J,358.3,27730,1,4,0)
 ;;=4^D58.2
 ;;^UTILITY(U,$J,358.3,27730,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,27731,0)
 ;;=C88.8^^132^1320^101
 ;;^UTILITY(U,$J,358.3,27731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27731,1,3,0)
 ;;=3^Malig Immunoproliferative Diseases,Other
 ;;^UTILITY(U,$J,358.3,27731,1,4,0)
 ;;=4^C88.8
 ;;^UTILITY(U,$J,358.3,27731,2)
 ;;=^5001750
 ;;^UTILITY(U,$J,358.3,27732,0)
 ;;=D70.8^^132^1320^170
 ;;^UTILITY(U,$J,358.3,27732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27732,1,3,0)
 ;;=3^Neutropenia,Other
 ;;^UTILITY(U,$J,358.3,27732,1,4,0)
 ;;=4^D70.8
 ;;^UTILITY(U,$J,358.3,27732,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,27733,0)
 ;;=D59.4^^132^1320^171
 ;;^UTILITY(U,$J,358.3,27733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27733,1,3,0)
 ;;=3^Nonautoimmune Hemolytic Anemias,Other
 ;;^UTILITY(U,$J,358.3,27733,1,4,0)
 ;;=4^D59.4
 ;;^UTILITY(U,$J,358.3,27733,2)
 ;;=^5002326
 ;;^UTILITY(U,$J,358.3,27734,0)
 ;;=D69.59^^132^1320^177
 ;;^UTILITY(U,$J,358.3,27734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27734,1,3,0)
 ;;=3^Secondary Thrombocytopenia,Other
 ;;^UTILITY(U,$J,358.3,27734,1,4,0)
 ;;=4^D69.59
 ;;^UTILITY(U,$J,358.3,27734,2)
 ;;=^5002369
 ;;^UTILITY(U,$J,358.3,27735,0)
 ;;=C22.7^^132^1320^44
 ;;^UTILITY(U,$J,358.3,27735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27735,1,3,0)
 ;;=3^Carcinomas of Liver,Other Spec
 ;;^UTILITY(U,$J,358.3,27735,1,4,0)
 ;;=4^C22.7
 ;;^UTILITY(U,$J,358.3,27735,2)
 ;;=^5000938
 ;;^UTILITY(U,$J,358.3,27736,0)
 ;;=D75.89^^132^1320^54
 ;;^UTILITY(U,$J,358.3,27736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27736,1,3,0)
 ;;=3^Diseases of Blood/Blood-Forming Organs,Other Spec
 ;;^UTILITY(U,$J,358.3,27736,1,4,0)
 ;;=4^D75.89
 ;;^UTILITY(U,$J,358.3,27736,2)
 ;;=^5002392
 ;;^UTILITY(U,$J,358.3,27737,0)
 ;;=D47.Z9^^132^1320^169
 ;;^UTILITY(U,$J,358.3,27737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27737,1,3,0)
 ;;=3^Neop Lymphoid,Hematopoietic & Related Tissue,Uncertain Behavior,Other
 ;;^UTILITY(U,$J,358.3,27737,1,4,0)
 ;;=4^D47.Z9
 ;;^UTILITY(U,$J,358.3,27737,2)
 ;;=^5002262
 ;;^UTILITY(U,$J,358.3,27738,0)
 ;;=D05.82^^132^1320^32
 ;;^UTILITY(U,$J,358.3,27738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27738,1,3,0)
 ;;=3^Carcinoma in Situ Left Breast,Other Spec Type
 ;;^UTILITY(U,$J,358.3,27738,1,4,0)
 ;;=4^D05.82
 ;;^UTILITY(U,$J,358.3,27738,2)
 ;;=^5001934
 ;;^UTILITY(U,$J,358.3,27739,0)
 ;;=D05.81^^132^1320^34
 ;;^UTILITY(U,$J,358.3,27739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27739,1,3,0)
 ;;=3^Carcinoma in Situ Right Breast,Oth Spec Type
 ;;^UTILITY(U,$J,358.3,27739,1,4,0)
 ;;=4^D05.81
 ;;^UTILITY(U,$J,358.3,27739,2)
 ;;=^5001933
 ;;^UTILITY(U,$J,358.3,27740,0)
 ;;=D05.80^^132^1320^36
 ;;^UTILITY(U,$J,358.3,27740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27740,1,3,0)
 ;;=3^Carcinoma in Situ Unspec Breast,Oth Spec Type
 ;;^UTILITY(U,$J,358.3,27740,1,4,0)
 ;;=4^D05.80
 ;;^UTILITY(U,$J,358.3,27740,2)
 ;;=^5001932
 ;;^UTILITY(U,$J,358.3,27741,0)
 ;;=D56.8^^132^1320^182
 ;;^UTILITY(U,$J,358.3,27741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,27741,1,3,0)
 ;;=3^Thalassemias,Other
